Evaluation of the immunogenicity and vaccine potential of recombinant Plasmodium falciparum merozoite surface protein 8

Infection and Immunity

Volumn 80, Issue 7, 2012, Pages 2473-2484

  Alaro, James R ^a   Angov, Evelina ^b   Lopez, Ana M ^a   Zhou, Hong ^c   Long, Carole A ^a,c   Burns, James M ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINE; ASPARTIC ACID; RECOMBINANT PLASMODIUM FALCIPARUM MEROZOITE SURFACE PROTEIN 8; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; DRUG SCREENING; IMMUNOGENICITY; MALE; MEROZOITE; MICROBIAL GROWTH; MOUSE; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHIZONT; T LYMPHOCYTE;

EID: 84864800650     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00211-12     Document Type: Article

References (54)

1. Alaro Jr, Lynch MM, Burns JM, Jr. 2010. Protective immune responses elicited by immunization with a chimeric blood-stage malaria vaccine persist but are not boosted by Plasmodium yoelii challenge infection. Vaccine 28:6876-6884.
2. Anders RF, Coppel RL, Brown GV, Kemp DJ. 1988. Antigens with repeated amino acid sequences from the asexual blood stages of Plasmodium falciparum. Prog. Allergy 41:148 -172.
3. Angov E, et al. 2003. Development and preclinical analysis of a Plasmodium falciparum merozoite surface protein-1(42) malaria vaccine. Mol. Biochem. Parasitol. 128:195-204.
4. Angov E, Hillier CJ, Kincaid RL, Lyon JA. 2008. Heterologous protein expression is enhanced by harmonizing the codon usage frequencies of the target gene with those of the expression host. PLoS One 3:e2189. doi: 10.1371/journal.pone.0002189.
5. Black CG, Wu T, Wang L, Hibbs AR, Coppel RL. 2001. Merozoite surface protein 8 of Plasmodium falciparum contains two epidermal growth factor-like domains. Mol. Biochem. Parasitol. 114:217-226.
6. Black CG, Wu T, Wang L, Topolska AE, Coppel RL. 2005. MSP8 is a nonessential merozoite surface protein in Plasmodium falciparum. Mol. Biochem. Parasitol. 144:27-35.
7. Blackman MJ, Heidrich HG, Donachie S, McBride JS, Holder AA. 1990. A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion-inhibiting antibodies. J. Exp. Med. 172:379 -382.
8. Boyle MJ, et al. 2010. Isolation of viable Plasmodium falciparum merozoites to define erythrocyte invasion events and advance vaccine and drug development. Proc. Natl. Acad. Sci. U. S. A. 107:14378 -14383.
9. Bozdech Z, et al. 2003. The transcriptome of the intraerythrocytic developmental cycle of Plasmodium falciparum. PLoS Biol. 1:e5. doi:10.1371/ journal.pbio.0000005.
10. Burns JM, Jr, Belk CC, Dunn PD. 2000. A protective glycosylphosphatidylinositol-anchored membrane protein of Plasmodium yoelii trophozoites and merozoites contains two epidermal growth factor-like domains. Infect. Immun. 68:6189-6195.
11. Burns JM, Jr, et al. 1989. A protective monoclonal antibody recognizes a variant-specific epitope in the precursor of the major merozoite surface antigen of the rodent malarial parasite Plasmodium yoelii. J. Immunol. 142:2835-2840.
12. Chappel JA, Holder AA. 1993. Monoclonal antibodies that inhibit Plasmodium falciparum invasion in vitro recognise the first growth factor-like domain of merozoite surface protein-1. Mol. Biochem. Parasitol. 60:303- 311.
13. Chowdhury DR, Angov E, Kariuki T, Kumar N. 2009. A potent malaria transmission blocking vaccine based on codon harmonized full length Pfs48/45 expressed in Escherichia coli. PLoS One 4:e6352. doi:10.1371/ journal.pone.0006352.
14. Collins CR, et al. 2007. Fine mapping of an epitope recognized by an invasion-inhibitory monoclonal antibody on the malaria vaccine candidate apical membrane antigen 1. J. Biol. Chem. 282:7431-7441.
15. Cowman AF, et al. 1985. Conserved sequences flank variable tandem repeats in two S-antigen genes of Plasmodium falciparum. Cell 40:775- 783.
16. Daly TM, Long CA. 1995. Humoral response to a carboxyl-terminal region of the merozoite surface protein-1 plays a predominant role in controlling blood-stage infection in rodent malaria. J. Immunol. 155: 236-243.
17. de Marco A. 2009. Strategies for successful recombinant expression of disulfide bond-dependent proteins in Escherichia coli. Microb. Cell Fact. 8:26.
18. Desjardins RE, Canfield CJ, Haynes JD, Chulay JD. 1979. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob. Agents Chemother. 16:710 -718.
19. Dluzewski AR, et al. 2008. Formation of the food vacuole in Plasmodium falciparum: a potential role for the 19 kDa fragment of merozoite surface protein 1 (MSP1(19)). PLoS One 3:e3085. doi:10.1371/journal.pone. 0003085.
20. Drew DR, O'Donnell RA, Smith BJ, Crabb BS. 2004. A common crossspecies function for the double epidermal growth factor-like modules of the highly divergent plasmodium surface proteins MSP-1 and MSP-8. J. Biol. Chem. 279:20147-20153.
21. Drew DR, Sanders PR, Crabb BS. 2005. Plasmodium falciparum merozoite surface protein 8 is a ring-stage membrane protein that localizes to the parasitophorous vacuole of infected erythrocytes. Infect. Immun. 73: 3912-3922.
22. Egan A, Waterfall M, Pinder M, Holder A, Riley E. 1997. Characterization of human T- and B-cell epitopes in the C terminus of Plasmodium falciparum merozoite surface protein 1: evidence for poor T-cell recognition of polypeptides with numerous disulfide bonds. Infect. Immun. 65: 3024-3031.
23. Egan AF, et al. 1996. Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1. J. Infect. Dis. 173:765- 769.
24. Feachem RG, et al. 2010. Shrinking the malaria map: progress and prospects. Lancet 376:1566 -1578.
25. Hackett F, Sajid M, Withers-Martinez C, Grainger M, Blackman MJ. 1999. PfSUB-2: a second subtilisin-like protein in Plasmodium falciparum merozoites. Mol. Biochem. Parasitol. 103:183-195.
26. Harris PK, et al. 2005. Molecular identification of a malaria merozoite surface sheddase. PLoS Pathog. 1:241-251. doi:10.1371/journal.ppat. 0010029.
27. Hensmann M, et al. 2004. Disulfide bonds in merozoite surface protein 1 of the malaria parasite impede efficient antigen processing and affect the in vivo antibody response. Eur. J. Immunol. 34:639-648.
28. Hillier CJ, et al. 2005. Process development and analysis of liver-stage antigen 1, a preerythrocyte-stage protein-based vaccine for Plasmodium falciparum. Infect. Immun. 73:2109 -2115.
29. Hirunpetcharat C, et al. 1997. Complete protective immunity induced in mice by immunization with the 19-kilodalton carboxyl-terminal fragment of the merozoite surface protein-1 (MSP1[19]) of Plasmodium yoelii expressed in Saccharomyces cerevisiae: correlation of protection with antigen-specific antibody titer, but not with effector CD4+ T cells. J. Immunol. 159:3400 -3411.
30. Holder AA. 2009. The carboxy-terminus of merozoite surface protein 1: structure, specific antibodies and immunity to malaria. Parasitology 136: 1445-1456.
31. Holder AA, Freeman RR. 1984. The three major antigens on the surface of Plasmodium falciparum merozoites are derived from a single high molecular weight precursor. J. Exp. Med. 160:624-629.
32. Huaman MC, et al. 2008. Ex vivo cytokine and memory T cell responses to the 42-kDa fragment of Plasmodium falciparum merozoite surface protein-1 in vaccinated volunteers. J. Immunol. 180:1451-1461.
33. Kumar S, et al. 1995. Immunogenicity and in vivo efficacy of recombi-nant Plasmodium falciparum merozoite surface protein-1 in Aotus monkeys. Mol. Med. 1:325-332.
34. Li X, et al. 2004. A coligand complex anchors Plasmodium falciparum merozoites to the erythrocyte invasion receptor band 3. J. Biol. Chem. 279:5765-5771.
35. Ling IT, Ogun SA, Holder AA. 1994. Immunization against malaria with a recombinant protein. Parasite Immunol. 16:63- 67.
36. Lyon JA, Geller RH, Haynes JD, Chulay JD, Weber JL. 1986. Epitope map and processing scheme for the 195,000-dalton surface glycoprotein of Plasmodium falciparum merozoites deduced from cloned overlapping segments of the gene. Proc. Natl. Acad. Sci. U. S. A. 83:2989 -2993.
37. Magowan C, et al. 2000. Plasmodium falciparum histidine-rich protein 1 associates with the band 3 binding domain of ankyrin in the infected red cell membrane. Biochim. Biophys. Acta 1502:461- 470.
38. McBride JS, Heidrich HG. 1987. Fragments of the polymorphic Mr 185,000 glycoprotein from the surface of isolated Plasmodium falciparum merozoites form an antigenic complex. Mol. Biochem. Parasitol. 23:71-84.
39. Miura K, et al. 2008. Comparison of biological activity of human antiapical membrane antigen-1 antibodies induced by natural infection and vaccination. J. Immunol. 181:8776-8783.
40. Nussenzweig V, Nussenzweig RS. 1985. Circumsporozoite proteins of malaria parasites. Cell 42:401- 403.
41. O'Donnell RA, et al. 2001. Antibodies against merozoite surface protein (MSP)-1(19) are a major component of the invasion-inhibitory response in individuals immune to malaria. J. Exp. Med. 193:1403-1412.
42. Ogutu BR, et al. 2009. Blood stage malaria vaccine eliciting high antigenspecific antibody concentrations confers no protection to young children in Western Kenya. PLoS One 4:e4708. doi:10.1371/journal.pone.0004708.
43. Pachebat JA, et al. 2007. Extensive proteolytic processing of the malaria parasite merozoite surface protein 7 during biosynthesis and parasite release from erythrocytes. Mol. Biochem. Parasitol. 151:59-69.
44. Pachebat JA, et al. 2001. The 22 kDa component of the protein complex on the surface of Plasmodium falciparum merozoites is derived from a larger precursor, merozoite surface protein 7. Mol. Biochem. Parasitol. 117:83- 89.
45. Painter HJ, Morrisey JM, Mather MW, Vaidya AB. 2007. Specific role of mitochondrial electron transport in blood-stage Plasmodium falciparum. Nature 446:88 -91.
46. Pusic KM, et al. 2011. T cell epitope regions of the P. falciparum MSP1-33 critically influence immune responses and in vitro efficacy of MSP1-42 vaccines. PLoS One 6:e24782. doi:10.1371/journal.pone.0024782.
47. Shi Q, Cernetich-Ott A, Lynch MM, Burns JM, Jr. 2006. Expression, localization, and erythrocyte binding activity of Plasmodium yoelii merozoite surface protein-8. Mol. Biochem. Parasitol. 149:231-241.
48. Shi Q, et al. 2005. Alteration in host cell tropism limits the efficacy of immunization with a surface protein of malaria merozoites. Infect. Immun. 73:6363- 6371.
49. Shi Q, Lynch MM, Romero M, Burns JM, Jr. 2007. Enhanced protection against malaria by a chimeric merozoite surface protein vaccine. Infect. Immun. 75:1349 -1358.
50. Shi YP, et al. 1996. Natural immune response to the C-terminal 19-kilodalton domain of Plasmodium falciparum merozoite surface protein 1. Infect. Immun. 64:2716 -2723.
51. Smythe JA, et al. 1988. Identification of two integral membrane proteins of Plasmodium falciparum. Proc. Natl. Acad. Sci. U. S. A. 85:5195-5199.
52. Thanaraj TA, Argos P. 1996. Ribosome-mediated translational pause and protein domain organization. Protein Sci. 5:1594 -1612.
53. Trucco C, et al. 2001. The merozoite surface protein 6 gene codes for a 36 kDa protein associated with the Plasmodium falciparum merozoite surface protein-1 complex. Mol. Biochem. Parasitol. 112:91-101.
54. Waller KL, Cooke BM, Nunomura W, Mohandas N, Coppel RL. 1999. Mapping the binding domains involved in the interaction between the Plasmodium falciparum knob-associated histidine-rich protein (KAHRP) and the cytoadherence ligand P. falciparum erythrocyte membrane protein 1 (PfEMP1). J. Biol. Chem. 274:23808 -23813.